Deutsche Bank AG Takes $2.48 Million Position in Medpace Holdings, Inc. $MEDP

Key Points

• Deutsche Bank acquired a new Medpace position worth approximately $2.48 million, purchasing 4,677 shares during the second quarter. Institutional investors collectively own 77.98% of the company.
• Analysts maintain a generally cautious outlook, with three Buy ratings and ten Holds; the consensus rating is Hold with a $584.18 price target, below the reported $611.57 share price.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS and $707.33 million in revenue, while revenue grew 17.2% year over year. However, insiders—including the CEO and a vice president—sold shares, with insiders selling roughly $79.4 million worth of stock over the past quarter.

Deutsche Bank AG purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,677 shares of the company's stock, valued at approximately $2,477,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BOKF NA grew its stake in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company's stock worth $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock worth $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. lifted its holdings in Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company's stock worth $253,000 after buying an additional 24 shares during the last quarter. Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock worth $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC grew its position in shares of Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after acquiring an additional 26 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. TD Cowen upped their price target on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Leerink Partners set a $620.00 target price on shares of Medpace in a report on Thursday, July 23rd. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $584.18.

Medpace Stock Down 1.2%

Shares of NASDAQ:MEDP opened at $611.57 on Friday. The company's 50-day moving average price is $562.52 and its 200 day moving average price is $493.80. The company has a market cap of $17.07 billion, a PE ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business earned $3.10 earnings per share. Medpace's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares of the company's stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 27,174 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the transaction, the chief executive officer owned 561,195 shares of the company's stock, valued at $347,261,854.05. This represents a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 129,963 shares of company stock worth $79,364,624. Insiders own 20.50% of the company's stock.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source